Skip to main content
SpringerLink
Log in

Phosphodiesterase Inhibitors

Do the Risks Outweigh the Benefits?

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Despite the justifiable concern about the use of oral cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitors, the intravenous preparations are clearly effective in the treatment of acute heart failure, whether it occurs de novo or complicating chronic congestive heart failure (CHF), and in low output states following cardiac surgery. There are no grounds to curtail their use in these areas, though any advantages over conventional agents such as dobutamine need further investigation with regard to end-points other than haemodynamic parameters. The long term use of oral cAMP PDE inhibitors in the treatment of chronic CHF should remain restricted by the increase in mortality now confirmed in severe CHF. However, in view of the distressing nature of the condition there remain subgroups of patients in whom the benefits may outweigh the risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anderson JL, Baim DS, Fein SA, Goldstein RA, Le Jemtel TH, et al. for the Milrinone Investigators and their associates. Efficacy and safety of sustained (48 hour) intravenous infusion of milrinone in patients with severe congestive heart failure: a multicenter study. Journal of the American College of Cardiology 9: 711–722, 1987

    Article  PubMed  CAS  Google Scholar 

  • Baim DS. Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. American Journal of Cardiology 63: 23A–26A, 1989

    Article  PubMed  CAS  Google Scholar 

  • Captopril Multicenter Research Group. A placebo controlled trial of Captopril in refractory chronic congestive heart failure. Journal of the American College of Cardiology 2: 755–763, 1983

    Article  Google Scholar 

  • Cohen-Solal A, for the VO2 French Study Group. Improving exercise tolerance in patients with chronic heart failure: should we treat the heart or periphery? European Heart Journal 10: 866–871, 1989

    PubMed  CAS  Google Scholar 

  • Cohn JA, Johnson G, Ziesche S, Cobb F, Francis G, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. New England Journal of Medicine 325:303–310, 1991

    Article  PubMed  CAS  Google Scholar 

  • Cohn JN. Inotropic therapy for heart failure. Paradise postponed. New England Journal of Medicine 320: 729–731, 1989

    Article  PubMed  CAS  Google Scholar 

  • Colucci WS, Braunwald E, Fifer MA, Jaski BE, Wright RF. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 73(Suppl. III): 175, 1986

    Google Scholar 

  • CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine 316: 1429–1435, 1987

    Article  Google Scholar 

  • Cowley AJ, Fullwood L, Hampton JR, Muller AF, Stainer K. The effects of enoximone in patients with heart failure which is uncontrolled by Captopril and diuretics. International Journal of Cardiology 28: 45–53, 1990

    Article  Google Scholar 

  • Cowley AJ, Hampton JR, Rowley JM, Stainer K. Abnormalities of the peripheral circulation and respiratory function in patients with severe heart failure. British Heart Journal 55: 75–80, 1986b

    Article  PubMed  CAS  Google Scholar 

  • Cowley AJ, Hampton JR, Rowley JM, Stainer K, Wynne RD. Comparison of the effects of Captopril and enoximone in patients with severe heart failure: a placebo controlled double blind study. International Journal of Cardiology 24: 311–316, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cowley AJ, Hampton JR, Rowley JM, Stainer K, Wynne RD. Symptomatic assessment of patients with heart failure: double blind comparison of increasing doses of diuretics and Captopril in moderate heart failure. Lancet 2: 770–772, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Cowley AJ. Enoximone in severe congestive heart failure — deleterious effect on mortality but improvement in quality of life. British Heart Journal 69: 15, 1993

    Google Scholar 

  • Crawford MH Intravenous use of enoximone. American Journal of Cardiology 60: 42C–45C, 1987

    Google Scholar 

  • DiBianco R, Shabetai R, Silverman B, Leier CV, Benotti JR, with the Amrinone Multicenter Study Investigators. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal trial. Journal of the American College of Cardiology 4: 855–866, 1984

    Article  PubMed  CAS  Google Scholar 

  • DiBianco R, Kostuk W, Moran J, Schlant R, Shabetai R, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. New England Journal of Medicine 320: 677–683, 1989

    Article  PubMed  CAS  Google Scholar 

  • Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. New England Journal of Medicine 329: 149–155, 1993

    Article  PubMed  CAS  Google Scholar 

  • Fitzpatrick PG, Baggs JG, Biddle TL, Cinquegranin MP, Hood WB, et al. Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: a dose-ranging study. American Heart Journal 114: 97–105, 1987

    Article  PubMed  CAS  Google Scholar 

  • Franciosa JA, Cohn JN, Goldsmith SR. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. American Journal of Medicine 69: 559–566, 1980

    Article  PubMed  CAS  Google Scholar 

  • Franciosa JA, Levine TB, Park M. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. American Journal of Cardiology 47: 33–39, 1981

    Article  PubMed  CAS  Google Scholar 

  • Francis GS, Cohn JN, Goldsmith SR, Levine TB, Olivari M, et al. Acute vasoconstrictor response to intravenous furosemide in patients with congestive heart failure. Annals of Internal Medicine 103: 1–6, 1985

    PubMed  CAS  Google Scholar 

  • George M, Atallah G, Bastien O, Durand PG, Estanove S, et al. Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output following valvular surgery. Archives des Maladies du Coeur et des Vaisseaux 83: 57–62, 1990

    PubMed  Google Scholar 

  • Gilbert EM, Hershberger RE, Watson F. Additivity of the effects of enoximone and dobutamine in the failing human heart. Circulation 76 (Suppl.): 225, 1987

    Google Scholar 

  • Goldenberg IF, Cohn JN. New inotropic drugs for heart failure. Journal of the American Medical Association 258: 493, 1987

    Article  PubMed  CAS  Google Scholar 

  • Grose R, Greenberg M, Le Jemtel TH, Strain J. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. Journal of the American College of Cardiology 7: 1107–1113, 1986

    Article  PubMed  CAS  Google Scholar 

  • Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. American Heart Journal 123: 95–103, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ludmer PL, Arnold MO, Braunwald E, Colucci WS, Ganz P, et al. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 73: 130–137, 1985

    Article  Google Scholar 

  • Maskin CS, Chadwick B, Le Jemtel TH, Sinoway MD, Sonnenblick EH. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 67: 1065–1070, 1983

    Article  PubMed  CAS  Google Scholar 

  • Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 71: 963–971, 1985

    Article  PubMed  CAS  Google Scholar 

  • Monrad ES, Baim DS, Lanoue AS, Smith HS. Milrinone, dobutamine and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73(Suppl. III): 168–174, 1986

    Google Scholar 

  • Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, et al. Effect of oral milrinone on mortality in severe chronic heart failure. New England Journal of Medicine 325: 1468–1475, 1991

    Article  PubMed  CAS  Google Scholar 

  • Simonton CA, Chatterjee K, Cody RJ, Daly P, Kubo SH, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. Journal of the American College of Cardiology 6: 453–459, 1985

    Article  PubMed  CAS  Google Scholar 

  • SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine 325: 293–302, 1991

    Article  Google Scholar 

  • Thormann J, Dieterich HA, Hueting J, Kremer P, Mitrovic V, et al. Enoximone: true inotropic effects? Do they cause ischaemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique. Cardiovascular Drugs and Therapy 4: 1403–1416, 1990

    Article  PubMed  CAS  Google Scholar 

  • Uretsky BF, Benotti J, Dec GW, Herrmann HC, Jessup M, et al. for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82: 774–780, 1990

    Article  PubMed  CAS  Google Scholar 

  • Vincent J-L, Carlier E, Berre J. Administration of enoximone in cardiogenic shock. American Journal of Cardiology 62: 419–423, 1988

    Article  PubMed  CAS  Google Scholar 

  • Wilmshurst PT, Coltart DJ, Dawson JR, Dittrich HC, Jenkins BS, et al. Effects of intracoronary and intravenous amrinone infusions in patients with cardiac failure and patients with near normal cardiac function. British Heart Journal 53: 493–506, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wilson JR, Ferraro N, Martin JL, Schwarty D. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation 69: 1079–1087, 1984

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University Hospital, Derby Road, Nottingham, NG7 2UH, England

    Richard Andrews & Alan J. Cowley

Authors
  1. Richard Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan J. Cowley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andrews, R., Cowley, A.J. Phosphodiesterase Inhibitors. Drug-Safety 9, 404–409 (1993). https://doi.org/10.2165/00002018-199309060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199309060-00003

Keywords

Search

Navigation